{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptan&page=14", "query": { "intervention": "Triptan", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1251, "total_pages": 126, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptan&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptan&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T20:14:47.683Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07053917", "title": "Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stroke", "Chronic Stroke", "Intracerebral Haemorrhage", "Intracerebral Haemorrhage (ICH)", "Intracerebral Hemorrhage Basal Ganglia", "Ischemic Stroke", "Ischemic Stroke and Hemorrhagic Stroke", "Hemiparesis After Stroke", "Hemiplegia Following Ischemic Stroke", "Hemiplegia and Hemiparesis", "Hemiplegia and/or Hemiparesis Following Stroke", "Middle Cerebral Artery Stroke" ], "interventions": [ { "name": "Psilocybin (Usona Institute)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-02-09", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07053917" }, { "nct_id": "NCT01445535", "title": "Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Peripheral Lymphoma", "Gamma Delta Hepatosplenic T-Cell Lymphoma", "Subcutaneous Panniculitis-Like T-Cell Lymphoma", "NK T-Cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Siplizumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2009-01-13", "completion_date": "2020-10-22", "has_results": true, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445535" }, { "nct_id": "NCT07138443", "title": "Influence of Melatonin on Cardiovascular and Thermoregulatory Responses to Stress", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress", "Mental Stress" ], "interventions": [ { "name": "Melatonin 3 MG Oral Tablet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo Oral Tablet", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Baylor University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2025-08-01", "completion_date": "2026-07-20", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 1, "location_summary": "Waco, Texas", "locations": [ { "city": "Waco", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138443" }, { "nct_id": "NCT00140140", "title": "A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IV (Metastatic) Breast Cancer" ], "interventions": [ { "name": "ABI-007", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "G-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2005-08", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 2, "location_summary": "Duarte, California • Seattle, Washington", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00140140" }, { "nct_id": "NCT01527149", "title": "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Mantle Cell Lymphoma", "Stage II Contiguous Mantle Cell Lymphoma", "Stage II Non-Contiguous Mantle Cell Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 37, "start_date": "2011-12-06", "completion_date": "2024-01-11", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 2, "location_summary": "Buffalo, New York • Nashville, Tennessee", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01527149" }, { "nct_id": "NCT00574496", "title": "Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mechlorethamine hydrochloride", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "13 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2007-11-13", "completion_date": "2022-08-02", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574496" }, { "nct_id": "NCT00002318", "title": "A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Doxorubicin hydrochloride (liposomal)", "type": "DRUG" }, { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sequus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 28, "location_summary": "Berkeley, California • Beverly Hills, California • Encino, California + 16 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002318" }, { "nct_id": "NCT00000620", "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Diseases", "Hypercholesterolemia", "Hypertension", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Coronary Disease" ], "interventions": [ { "name": "Anti-hyperglycemic Agents", "type": "DRUG" }, { "name": "Anti-hypertensive Agents", "type": "DRUG" }, { "name": "Blinded fenofibrate or placebo plus simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 10251, "start_date": "1999-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 6, "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000620" }, { "nct_id": "NCT00641160", "title": "Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonhematologic Malignancies" ], "interventions": [ { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Metronome Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-03", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2008-09-26", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00641160" }, { "nct_id": "NCT05600686", "title": "Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Double-Expressor Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Loncastuximab Tesirine", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-05-24", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-24T20:14:47.683Z", "location_count": 2, "location_summary": "Sacramento, California • San Diego, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05600686" } ] }